Clinical Trial Detail

NCT ID NCT01750281
Title Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors AstraZeneca

lung non-small cell carcinoma



Docetaxel + Selumetinib

Age Groups: adult

Additional content available in CKB BOOST